Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Pacira BioSciences, Inc. (PCRX)

37.8898   -0.71 (-1.84%) 03-24 11:13
Open: 38.21 Pre. Close: 38.6
High: 38.48 Low: 37.79
Volume: 155,301 Market Cap: 1,741(M)

Technical analysis

as of: 2023-03-24 10:46:23 AM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 49.02     One year: 52.01
Support: Support1: 37.83    Support2: 31.47
Resistance: Resistance1: 41.97    Resistance2: 44.52
Pivot: 39.65
Moving Average: MA(5): 39.2     MA(20): 40.3
MA(100): 42.48     MA(250): 52.8
MACD: MACD(12,26): -0.5     Signal(9): -0.3
Stochastic oscillator: %K(14,3): 8.8     %D(3): 16.1
RSI: RSI(14): 40.5
52-week: High: 82.16  Low: 35.34
Average Vol(K): 3-Month: 547 (K)  10-Days: 452 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ PCRX ] has closed above bottom band by 5.2%. Bollinger Bands are 39.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 39.95 - 40.22 40.22 - 40.44
Low: 37.97 - 38.23 38.23 - 38.44
Close: 38.22 - 38.64 38.64 - 38.99

Company Description

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.

Headline News

Fri, 24 Mar 2023
With Pacira BioSciences, Inc.'s (NASDAQ:PCRX)) price down 6.9% this week, insiders might find some solace having sold US$2.2m worth of shares earlier this year. - Simply Wall St

Wed, 22 Mar 2023
Pacira BioSciences (PCRX) Announces Resignation of Yvonne ... -

Sat, 11 Mar 2023
Summit Global Investments Buys 4500 Shares of Pacira ... - MarketBeat

Thu, 09 Mar 2023
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q4 2022 Earnings Call Transcript - Yahoo Finance

Wed, 01 Mar 2023
Pacira's (PCRX) Q4 Earnings Match Estimates, Revenues Fall - Nasdaq

Thu, 23 Feb 2023
LPGA, Pacira BioSciences Partner to Raise Awareness of Non ... - LPGA

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Drug Manufacturers—Specialty & Generic
Shares Out. 46 (M)
Shares Float 45 (M)
% Held by Insiders 1.1 (%)
% Held by Institutions 111.8 (%)
Shares Short 4,500 (K)
Shares Short P.Month 4,950 (K)

Stock Financials

EPS 3.32
EPS Est Next Qtl 0.1
EPS Est This Year -0.21
EPS Est Next Year 0.91
Book Value (p.s.) 14.85
Profit Margin (%) 3.1
Operating Margin (%) 15.9
Return on Assets (ttm) 4.2
Return on Equity (ttm) 2.7
Qtrly Rev. Growth 31.1
Gross Profit (p.s.) 7.53
Sales Per Share 14.25
EBITDA (p.s.) 3.89
Qtrly Earnings Growth 0
Operating Cash Flow 126 (M)
Levered Free Cash Flow 88 (M)

Stock Valuations

PE Ratio 11.45
PEG Ratio 0.5
Price to Book value 2.56
Price to Sales 2.67
Price to Cash Flow 13.83

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.